TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways

Qiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu · 2024

Read TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways by Qiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11531577.txt.

Description

Background Sorafenib is a standard therapeutic agent for advanced hepatocellular carcinoma (HCC). However, its efficacy is moderate, as the survival of patients is prolonged for only a few months, and the response rate is low. The mechanism of low efficacy remains unclear.

Catalog record

CREATORQiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11531577

Browse the full library · About the Tower of Babel